Why combine DAPSA and PASI in PsA?

PsA requires assessment of multiple domains: peripheral arthritis (DAPSA), skin (PASI), axial disease (BASDAI/ASDAS), enthesitis, and dactylitis. No single score captures all domains; composite indices like SASDAS aim to simplify multidomain assessment.

What biologic therapies address both skin and joints in PsA?

IL-17A inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (guselkumab, risankizumab), and IL-12/23 inhibitor (ustekinumab) address both domains. TNFi and JAKi are effective for joints but less so for skin than IL-17/IL-23 agents.

How is minimum disease activity defined in PsA?

MDA in PsA requires ≥5/7: TJC68 ≤1, SJC66 ≤1, PASI ≤1 or BSA ≤3%, pain VAS ≤15, patient global ≤20, HAQ ≤0.5, ≤1 enthesitis tender points.

SASDAS Skin and Arthritis Combined Disease Activity

Calculate SASDAS (Skin and Arthritis Disease Activity Score), combining DAPSA for joint disease with PASI for skin disease in psoriatic arthritis. Provides a single composite score for comprehensive PsA management.

Use the full interactive calculator below, or

Related Calculators

DAPSA PsA

Hyper-niche Medical

PASI Psoriasis

Hyper-niche Medical

DLQI Dermatology

Hyper-niche Medical

SASDAS Skin and Arthritis Combined Disease Activity

Related Calculators

Frequently Asked Questions

Why combine DAPSA and PASI in PsA?

What biologic therapies address both skin and joints in PsA?

How is minimum disease activity defined in PsA?